Biohit Oyj Press Release 30.4.2014 at 3:20 pm local time (EEST)
Biohit Oyj now offers online shopping for European Union customers outside Finland also. Check out the www.biohitshop.com .
The Acetium® capsules and lozenges are the only products in the market which can significantly reduce carcinogenic acetaldehyde exposure.
The Acetium® capsules are meant to protect the stomach of persons with a low or anacidic stomach, for example due to atrophic gastritis or continued use of PPI´s (Proton Pump Inhibitors). Biohit has started two clinical trials with Acetium® capsule for prevention of migraine-type headache.
The Acetium® lozenge removes more than 90 per cent of the acetaldehyde dissolved in saliva during smoking and can possibly help with smoking cessation. Biohit has started a clinical intervention trial with Acetium® lozenge aimed at smoking cessation.
CEO Semi Korpela, Biohit Oyj: ´Our international online shopping is now open and orders can be placed also using mobile devices.´
Release about two clinical trials with Acetium® capsule for prevention of migraine-type headache: http://www.biohithealthcare.com/feed/news/166...e-headache
Release about a clinical intervention trial with Acetium® lozenge aimed at smoking cessation: http://www.biohithealthcare.com/feed/news/149...-cessation
Additional information:
CEO Semi Korpela, Biohit Oyj tel. +358 9 773 861 investor.relations@biohit.fi www.biohithealthcare.com
In order to reveal your acetaldehyde exposure check the www.acetium.com/test
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com .